3 completed, 2 recruiting, 2 unknown. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 2, Unknown 2 |
| Phase 2 | 6 | Completed 2, Recruiting 2, Unknown 2 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia chimeric antigen receptor T cell - Acute Myeloid Leukemia, Relapse Leukemia | Phase 1 / Phase 2 | Completed | Beijing Boren Hospital | 5 | 2021-04-08 | 2024-06-21 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
Leukemia, Myeloid, Acute (5) · Leukemia (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Lymphoma, Non-Hodgkin (2) · Anemia, Refractory, with Excess of Blasts (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Hematologic Neoplasms (1) · Hemoglobinopathies (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Biphenotypic, Acute (1) · Metabolism, Inborn Errors (1) · Multiple Myeloma (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Leukemia, Myeloid (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Leukemia (3) · Leukemia, Lymphoid (3) · Lymphoma (3) · Bone Marrow Diseases (2) · Neoplasms by Site (2) · Anemia (1)
Azacitidine (1) · Clinical Trials, Phase I as Topic (1) · revumenib (1)
Beijing Boren Hospital (1) · Children's Hospital of Philadelphia (1) · Chongqing Precision Biotech Co., Ltd (1) · Ciusss de L'Est de l'Île de Montréal (1) · Memorial Sloan Kettering Cancer Center (1) · Newave Pharmaceutical Inc (1) · Shenzhen University General Hospital (1)
China (3) · United States (3) · Canada (1) · Spain (1)
Denis-Claude Roy, MD PhD (1) · Jia Wei, M.D (1) · Jing Pan, MD/PhD (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Silvy Lachance, MD (1) · Timothy Olson, MD, PhD (1)